Oxford Cannabinoid Technologies - Early signs of revival in clinical activity
Oxford Cannabinoid Technologies (OCT) has announced its H124 results (to end-October 2023), an eventful period for the company, marked by successful clinical progression of lead asset OCT461201, albeit with some funding challenges. Key highlights included the initiation and subsequent positive safety data from OCT’s first Phase I clinical trial (Programme 1) and a foray into oncology (Programme 4). Tight funding conditions halted subsequent clinical progress, although the recently announced £1.3m R&D tax rebate, £1.2m fund-raise and planned clinical progression for second asset OCT130401 (Programme 2) offer signs of a potential revival in activity. We estimate that the fresh capital will support runway extension into Q4 CY24. Our valuation of the company stands at £25.3m or 2.6p per share, although we estimate the company needing additional funds towards the end of CY24 to further the company’s clinical pipeline.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.